Field management software has been making technological advancements through analytics, ML, and VRRead more...
Kardia Pro helps detect atrial fibrillation early to reduce the risk of patients having a stroke
Editor's note: Our Splash Health, Wellness and Wearables event is coming up on March 23 in San Francisco. We'll have Mario Schlosser (Founder & CEO of Oscar Health), Brian Singerman (Partner, Founders Fund), Steve Jurvetson (Draper Fisher Jurvetson), J. Craig Venter (Human Longevity), Lynne Chou (Partner, Kleiner Perkins), Michael Dixon (Sequoia Capital), Patrick Chung (Xfund), Check out the full lineup and register for tickets before they jump! If you want to invest as little as $2500 in our startup winners, join the Vator Investment Club (VIC).
Heart disease is the leading cause of death in the U.S., causing around 610,000 deaths in the United States every year. That’s 1 in every 4 deaths. Not only that, but it's expensive too: coronary heart disease costs the United States roughly $108 billion each year.
This is a very serious problem, one that technology companies like AliveCor, the developer of a device that can turn any smartphone into a clinical-quality ECG (electrocardiography) recorder, are tackling. On Thursday, the company made two big announcements, one involving a big new funding round, and the other a new kind of platform that uses artificial intelligence to help stop strokes.
First, AliveCor revealed that it has raised $30 million in Series D funding. The round was led by Omron Healthcare and Mayo Clinic.
The company had previously raised $13.5 million in venture funding from Burrill & Company, Khosla Ventures, Oklahoma Life Science Fund and Qualcomm Ventures.
AliveCor says that it will use the new money to "accelerate innovations in heart health and continue the rapid expansion of the business," as well as to expand its team.
"One key area of focus is engineers as the company looks to expand its focus to include engineers with specialized skills like A.I. We want to continue the engineering work we’ve been doing with Kardia Pro and become a leader when it comes to machine learning and EKGs," Vic Gundotra, CEO of AliveCor, told me.
New AI platform
In addition to the funding, AliveCor also made a major announcement regarding its platform, unveiling the U.S. release of Kardia Pro, an artificial intelligence-enabled platform for doctors to monitor patients.
"To manage heart disease and stroke risk, we knew that cardiologists wanted to see more than just EKGs from their patients. We created Kardia Pro to track important measures of physiology like weight, activity and blood pressure and for the first time, AI technology is used to create a personal heart profile for each user, enabling user identification," said Gundotra.
"This new platform enables doctors to be better doctors and patients to be more active participants in their own health. This is truly a revolution in healthcare and it drives the industry forward into the 21st century. Heart disease is the number one cause of death for men and women worldwide and Kardia Pro’s first AI-enabled platform helps the doctor see things that were previously not available to human eyes, and we’re just getting started on unlocking the secrets of heart health."
During the first month of usage of Kardia Mobile, AliveCor is able to learn about a user’s individualized heart profile. Their personalized heart profile can be used for two benefits.
"First, it helps keep the data clean. If a doctor is monitoring your health using Kardia Pro, she can be more confident that the data she is reviewing is truly her patients, and not someone else's," Gundotra said. "Second, and even more exciting, is that in the future, a heart profile may be able to find, and flag to your doctor, important changes in your ECG."
Kardia Pro is a platform designed for doctors, to allow them to monitor patients for early detection of atrial fibrillation. The patients who use Kardia Mobile include people with or at risk of a chronic heart condition called AFib or AF, a leading cause of stroke.
Other users include people who want to take proactive action against stroke and heart disease, such as those with a family history of heart disease or health-conscious people in general, as well as caregivers concerned about the heart health of a loved one and want to take an active role in the monitoring and management of their heart care.
Users of Kardia Mobile can start using Kardia Pro with their doctors if they prescribe and invite them to use the platform.
The new platform is part of whay made AliveCor a compelling investment for Omron Healthcare.
"AliveCor is compelling to us because of how proactive its platforms like Kardia Pro can make patients in their own healthcare. That kind of innovation means more awareness and real behavior change. Omron Healthcare’s mission is Going for Zero heart attack and stroke and we are connecting with partners who share this bold vision and are committed to pursuing it," Ranndy Kellogg, president and CEO of Omron Healthcare, told me.
AliveCor's core product is its Karbia Mobile ECG device, which records accurate ECGs and heart rate on their mobile device via the AliveCor app. Users just put their fingers on the device's electrodes, without any wires, patches or gels required and, as long as they are within 12 inches of their smartphone or tablet, it will take an EKG recording. Users just have to pay a one time fee of $99 to access Kardia Mobile.
The device allows users to track medications, symptoms, such as palpitations and shortness of breath, habits like caffeine or alcohol consumption, and activities like exercise or sleep. Users can also record voice memos with each EKG to record their how they are feeling. Ultimately, this makes it easier for patients to share ECGs, AF episodes and symptoms they are feeling with their doctor.
Over 5 million ECGs have been recorded from around the world.
Artificial intelligence in healthcare
The use of AI in healthcare has been on the rise. In 2012, there were only 20 companies in the digital healthspace that raised funds; by 2016, the number had more than tripled to 70 companies, according to data from CB Insights. 50 companies have raised their first round of funding in just the last two years.
In all, CB Insights identifed 106 AI healthcare companies around the world, including Atomwise, Sense.ly, Flatiron Health, WellTok, Zephyr Health, Medaware, Lumiata and Ginger.io.
In February 2016, speaking at Vator Splash Health, Gundotra was asked about what new technologies that he was seeing coming up. His answer was deep learning and artificial intelligence.
"What we can do with this data? Does exercise help or hurt your heart condition? Today we have the data to know, from millions of people, and that is just one of many examples of the kinds of insights we're about to derive for the first time. And I think it's going to lead to much better outcomes."
He predicted that such technology would be revolutionizing healthcare within 18 months. Only 13 months later, it's already here.
"Partnering with AliveCor advances our path forward to build robust software programs that play a dynamic role in expanding heart health awareness, transforming the patient and caregiver dynamic and taking real steps toward eliminating heart attack and stroke," Kellogg said.
"We believe that advanced personal blood pressure monitors connected to dynamic software can teach healthy new habits and save lives. The prospect that AI can help identify risky behaviors, fuel physician insights and foster more patient-to-doctor knowledge is compelling for the entire healthcare field."
"We are excited to be supported by investors like Omron Healthcare and Mayo Clinic. These
partnerships further validate AliveCor as a medtech leader and we are looking forward to redefining
the role technology plays in delivering 21st century care," Gundotra said.
(Image source: alivecor.com)
Support VatorNews by Donating
Read more from our "Trends and news" series
The two companies are working together on contrast-enhanced mammographyRead more...
The company offers a supplement line that features a suite of hormone free systemsRead more...
Related Companies, Investors, and Entrepreneurs
Joined Vator on
Welltok, the leading consumer health enterprise Software as a Service company, is on a mission to empower consumers to achieve their optimal health. Its award-winning CaféWell Health Optimization Platform connects consumers with available and relevant benefits, resources and rewards by designing personalized action plans. Additionally, the company's technology-enabled services leverage both advanced analytics to derive meaningful consumer insights and multi-channel communications to reach consumers through the right channel with the right message. Welltok drives greater consumer engagement and healthcare value for customers across the healthcare continuum including payers, employers, government programs (Medicare and Medicaid) and providers.
Joined Vator on
Sensely’s avatar and chatbot-based platforms assist insurance plan members and patients with the insurance services and healthcare resources they need, when they need it. With offices in London and San Francisco, Sensely’s global teams provide virtual assistant solutions to insurance companies, pharmaceutical clients, and hospital systems worldwide.
Joined Vator on
Lumiata is a data science company that is transforming healthcare by enabling hospital networks, health insurance companies and risk bearing entities to become predictive-first: Continuously able to predict the health, risk and cost of individuals and populations in real time and at scale.
Lumiata combines the analytical power of big data and data science with the brilliance of physicians and medical science to deliver hyper-personalized, actionable analytics that enable the entire care team to continuously know what to do, for whom, when and why.
Lumiata is a venture-backed company based in Silicon Valley, comprised of clinicians, data scientists, engineers and experts in care delivery.